Abstract:
:Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two mainstays to reduce the risk of infection are vaccination and antibiotic prophylaxis. In this retrospective study, serologic response was analyzed after vaccination with a meningococcal vaccine in 23 PNH patients (median age 36 years; range 25 - 88 years; 15 males, 8 females) by measuring serum bactericidal assay (SBA) using rabbit complement (rSBA) titers against meningococcal serogroups A, C, W, and Y. Serologic protection was defined by an rSBA titer ≥1:8. Forty-three percent (10/23) were vaccinated more than once due to chronic eculizumab treatment. Overall serologic response for the meningococcal serogroups was A: 78% (18/23), C: 87% (20/23), W: 48% (11/23), and Y: 70% (16/23). No meningococcal infections have been observed. As immunological response to vaccines varies, the use of serologic response analyses is warranted. Re-vaccination with a tetravalent conjugate vaccine under eculizumab therapy every 3 years is essential or should be based on response rates. If meningococcal infection is suspected, standby therapy with ciprofloxacin and immediate medical evaluation are recommended. The novel vaccines covering serogroup B may even further reduce the risk for infection.
journal_name
Ann Hematoljournal_title
Annals of hematologyauthors
Alashkar F,Vance C,Herich-Terhürne D,Preising N,Dührsen U,Röth Adoi
10.1007/s00277-017-2924-ysubject
Has Abstractpub_date
2017-04-01 00:00:00pages
589-596issue
4eissn
0939-5555issn
1432-0584pii
10.1007/s00277-017-2924-yjournal_volume
96pub_type
杂志文章abstract::Imatinib is a new promising therapeutic option for chronic myeloid leukemia (CML) with efficacy even in the blast phase of the disease. However, most patients treated with imatinib in the blast phase develop progressive disease rapidly. Thus, treatment with imatinib has to be followed by other treatment strategies. Th...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-003-0643-z
更新日期:2003-05-01 00:00:00
abstract::Defects in central and peripheral tolerance are thought to contribute to life-threatening graft-versus-host disease (GvHD), a severe complication following allogeneic stem cell transplantation (SCT). Recent investigations have demonstrated regulatory T cells (Tregs) to suppress allogeneic immune reactions. Therefore, ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-010-1068-0
更新日期:2011-02-01 00:00:00
abstract::Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Pat...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-013-1784-3
更新日期:2013-11-01 00:00:00
abstract::Alterations in hemoglobin oxygen affinity can be detected by exposing blood to different PO2 and recording oxygen saturation, a method termed tonometry. It is the gold standard to measure the PO2 associated with 50 % oxygen saturation, the index used to quantify oxygen affinity (P50Tono). P50Tono is used in the evalua...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-012-1667-z
更新日期:2013-04-01 00:00:00
abstract::Malignant lymphomas are a heterogenous group of malignancies, belonging to the 10 most frequent types of cancers worldwide. In indolent lymphoma only patients with limited stage I/II (Ann Arbor) can be potentially cured by local irradiation. However, about 85% of cases present with advanced stage; for these patients n...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-004-0850-2
更新日期:2004-01-01 00:00:00
abstract::A 57-year-old man with acute myeloid leukemia (AML) French-American-British (FAB) 4 developed disseminated invasive cerebral and pulmonary aspergillosis during postinduction aplasia. According to international consensus, infection was categorized as probable (two host factors: deep neutropenia for >10 days and refract...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-003-0792-0
更新日期:2004-06-01 00:00:00
abstract::Lower dosage of total body irradiation (TBI) and chemotherapy in reduced-intensity conditioning (RIC) regimens prior to allogeneic stem cell transplantation have reduced the toxicity of the conditioning and non-relapse mortality. The FLAMSA-RIC protocol for high-risk patients with acute myeloid leukemia (AML) and myel...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-011-1253-9
更新日期:2012-01-01 00:00:00
abstract::Transplantation of autologous hematopoietic stem cells is a well established therapeutic procedure. Despite advances in efficacy of the stem cell mobilization and apheresis process until now a predictive factor for the expected stem cell yield before initiation of mobilization therapy could not be identified. The main...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-005-0074-0
更新日期:2006-06-01 00:00:00
abstract::Ruxolitinib is a promising option for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we describe ruxolitinib treatment for SR-aGVHD in HSCT patients with Epstein-Barr virus-associated hemophagocytic lymphohisti...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-019-03864-y
更新日期:2020-02-01 00:00:00
abstract::B cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematologic malignancy with limited treatment strategies. Histone deacetylases inhibitors (HDACis) are promising novel tools for cancer therapy, whose anti-tumor effects and the underlying mechanisms on B-ALL remain to be elucidated. Recently, Notch1 signali...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-012-1561-8
更新日期:2013-01-01 00:00:00
abstract::The current phase-II trial was initiated to assess the efficacy and toxicity of the Ida-FLAG regimen in patients with poor-risk acute myeloid leukemia (AML). Three subgroups of patients with AML were eligible for the study: (a) refractory, (b) first relapse, or (c) secondary AML (i.e., signs of trilineage myelodysplas...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/s002770050541
更新日期:1999-09-01 00:00:00
abstract::While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and optimize use of existing...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-010-0917-1
更新日期:2010-07-01 00:00:00
abstract::Indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) can induce or maintain peripheral immune tolerance. Impaired IDO-mediated tryptophan catabolism has been observed in autoimmune diseases. In order to investigate the effects of IDO-mediated tryptophan catabolism and IDO-expressing DCs in immune thro...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-012-1451-0
更新日期:2012-10-01 00:00:00
abstract::Chronic idiopathic neutropenia of adults (CINA) is a granulocytic disorder characterised by the "unexplained" decrease in the number of circulating neutrophils. Serum inflammatory cytokines and chemokines are increased in CINA. In addition, cytokines gene polymorphisms are associated with increased levels of respectiv...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-005-1066-9
更新日期:2005-10-01 00:00:00
abstract::In some instances, because of the lack of mass formation and the absence of prominent lymph node enlargement, diagnosis of lymphoma-associated hemophagocytic syndrome (LAHS) is difficult, which results in the development of progressive disease with unfavorable prognosis. Therefore, in the diagnosis of secondary hemoph...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-011-1239-7
更新日期:2012-01-01 00:00:00
abstract::The Wilms' tumor 1 (WT1) expression has been recognized in a substantial number of acute myeloid leukemia (AML) patients. Some studies indicated the association of diagnosed WT1 higher expression (WT1(H)) and poor outcome in the AML patients, while other studies had different opinions. Therefore, we performed a meta-a...
journal_title:Annals of hematology
pub_type: 杂志文章,meta分析
doi:10.1007/s00277-014-2295-6
更新日期:2015-06-01 00:00:00
abstract::In this study, the immunologic abnormalities of Iranian beta-thalassemia major patients were characterized, considering their clinical parameters including splenectomy status and iron overload. Serum samples and peripheral blood mononuclear cells were collected from 28 patients and 30 age- and sex-matched healthy indi...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0564-y
更新日期:2009-01-01 00:00:00
abstract::In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients ...
journal_title:Annals of hematology
pub_type: 杂志文章,随机对照试验
doi:10.1007/s00277-016-2638-6
更新日期:2016-05-01 00:00:00
abstract::Pulmonary infections are a major cause of morbidity and mortality in patients with hematologic malignancy. Bronchoscopy is at present still the traditional first investigation in immunosuppressed patients that have developed pulmonary infiltrates. There is limited data available on the validity of fiberoptic bronchosc...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-014-2172-3
更新日期:2015-01-01 00:00:00
abstract::This study outlines trends in quality of delivered non-Hodgkin's lymphoma (NHL) care in the Netherlands between 2007 and 2011 and to what extend this was influenced by the national Visible Care program, which aimed at increasing transparency by providing insight into the quality of healthcare. We analyzed data collect...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s00277-015-2340-0
更新日期:2015-07-01 00:00:00
abstract::Paul Kaznelson is credited with describing the first case of pure red cell aplasia. He was also known for his contribution to the discovery of the therapeutic role of splenectomy in idiopathic thrombocytopenic purpura. Most of his academic works appeared in 1910s and 1920s, when he used to work in Karl-Ferdinand Unive...
journal_title:Annals of hematology
pub_type: 传,历史文章,杂志文章
doi:10.1007/s00277-008-0553-1
更新日期:2008-11-01 00:00:00
abstract:PURPOSE AND METHODS:Nowadays more people are becoming older. The median age of a patient with non-Hodgkin's lymphoma (NHL) at diagnosis is over 60 years. The incidence of NHL in elderly has increased in the last decades. Therefore, in the future, NHL will be diagnosed more often in the elderly. Data of all patients in ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770000255
更新日期:2001-03-01 00:00:00
abstract::Hodgkin lymphoma (HL) in resource-poor population shows an early childhood peak with predominance of mixed cellularity (MCHL) and high Epstein-Barr virus (EBV) association, whereas HL in resource-rich population has a peak in ages 15-29 years with the predominance of nodular sclerosis (NSHL) and low EBV association. W...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究,评审
doi:10.1007/s00277-013-1837-7
更新日期:2013-12-01 00:00:00
abstract::In view of obscure clinical and biological significance of leukemic cells heterogeneity, we studied the efficacy of apoptosis, proliferation, and expression levels of the Bcl-2, MDR1, LRP, and BCRP genes in sorted CD34+ and CD34- subpopulations of childhood AML leukemic samples. In five out of nine cases, CD34+ cells ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0439-2
更新日期:2008-05-01 00:00:00
abstract::The prognostic value of peripheral blasts (PB) is not well-studied in patients with myelodysplastic syndromes (MDS). We evaluated the impact of PB on overall survival (OS) and transformation to acute myeloid leukemia (AML) in a large cohort. The MDS database at the Moffitt Cancer Center was retrospectively reviewed to...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-017-3186-4
更新日期:2018-02-01 00:00:00
abstract::To determine the value of aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis (IPA), we initiated a prospective randomized multicenter trial. The scheduled intent-to-treat interim analysis included 115 patients (30%) with prolonged neutropenia after chemotherapy for acute myeloid leuk...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1007/BF01697981
更新日期:1995-12-01 00:00:00
abstract::The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-009-0752-4
更新日期:2009-12-01 00:00:00
abstract::Treatment of relapse and primary progression in aggressive lymphoma remains unsatisfactory; outcome is still poor. Better treatment strategies are much needed for this patient population. The R1 study is a prospective multi-center phase I/II study evaluating a dose finding approach with a triple transplant regimen in ...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-016-2671-5
更新日期:2016-06-01 00:00:00
abstract::A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezom...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/s00277-009-0726-6
更新日期:2009-11-01 00:00:00
abstract::Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the MCL patients; however, complete remission rates are low and duration of response pro...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-011-1377-y
更新日期:2012-06-01 00:00:00